Cell Therapy for Advanced Pancreatic Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental cell therapy called MT-601 for people with advanced pancreatic cancer that has not worsened during standard chemotherapy (FOLFIRINOX or nab-paclitaxel/gemcitabine). The goal is to see if this new treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that is locally advanced (cannot be removed surgically) or has spread to other parts of the body.
- You need to have already received at least 4 rounds (about 2 months) of either the FOLFIRINOX or nab-paclitaxel plus gemcitabine chemotherapy regimen, and plan to complete 12 rounds of that regimen.
- Your cancer should not have worsened during that chemotherapy (i.e., it is stable or shrinking).
- You must be 18 or older, able to walk and care for yourself (ECOG performance status 0–1), and have proper heart, lung, kidney, and liver function.
- You cannot have certain other active cancers, uncontrolled infections, autoimmune diseases needing steroids, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with advanced pancreatic cancer that has spread and is not removable by surgery, after standard treatments like chemotherapy no longer work. The goal is to see if this experimental therapy can help shrink tumors or slow the disease.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
This trial tests a new drug called NRT6008 combined with standard chemotherapy for pancreatic cancer that cannot be surgically removed. The goal is to see if adding this new drug makes the chemotherapy work better and is safe.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.